Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751885 | 0.84 | IDO1 (0.35) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL1751884 | 0.84 | IDO1 (0.35) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL5820033 | 0.84 | IDO1 (0.35) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL1751842 | 0.84 | IDO1 (0.35) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL4848914 | 0.81 | CA1 (0.44) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL5819050 | 0.80 | IDO1 (0.33) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL5819046 | 0.80 | IDO1 (0.33) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL5819052 | 0.80 | IDO1 (0.33) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL14567496 | 0.80 | APLNR (0.37) | IDO1AGXTCA1CA2CASR | |
| SCHEMBL14253536 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148218-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1312608-B1 | Discodermolide analogues and their pharmaceutical use | NOVARTIS AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK R (US) | 2005-04-14 | — | — | US | disclosed |
| US-6833367-B2 | A polyhydroxy-polymethyl-8-tridecenoic acid 8-lactone compounds, as antitumor agents, anticarcinogenic agents | NOVARTIS AC (CH) | 2004-12-21 | — | — | US | disclosed |
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | PBK, BCKDK, ETV6 | IDO1 1376/4885AGXT 630/4885CA1 3468/4885 |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | PBK, HCCS, BCKDK | IDO1 2473/4885AGXT 455/4885CA1 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.